Strong mechanistic evidence + promising early human data = worth adding to the stack.
This protocol moves beyond the RCT-only tier to incorporate high-quality mechanistic research and early human trials where the signal is strong enough to be compelling. It's for people who understand they're operating on incomplete information — and are comfortable with that trade-off in exchange for potential early-mover advantage.